José Baselga

José Baselga founded Mosaic Biomedicals SL in 2013, Tango Therapeutics Sub, Inc. in 2017, and Tango Therapeutics, Inc. in 2017.
Dr. Baselga also founded Venthera, Inc. Dr. Baselga also formerly worked at The General Hospital Corp., as Chairman-Hematology & Oncology Division in 2013, Vall d'Hebron Institut d'Oncologia, as Director & Chairman-Medical Oncology Service from 1996 to 2010, Bristol Myers Squibb Co., as Independent Director in 2018, Varian Medical Systems, Inc., as Independent Director from 2017 to 2018, Exelixis, Inc., as Director, Aura Biosciences, Inc., as Director, Infinity Pharmaceuticals, Inc., as Independent Director from 2014 to 2017, American Society of Clinical Oncology, Inc., as Director in 2006, American Association for Cancer Research, as Director from 2008 to 2011, Massachusetts General Hospital Cancer Center, as Associate Director from 2010 to 2012, Breast International Group, as Director, Vall d'Hebron University Hospital, as Founding Director from 2007 to 2012, GRAIL LLC, as Director, Foghorn Therapeutics, Inc., as Independent Director from 2017 to 2021, AstraZeneca PLC, as Executive VP-Oncology Research & Development, Memorial Sloan Kettering Cancer Center, as Chief Medical Officer from 2013 to 2018, National Academy of Medicine (United States), as Member, Association of American Physicians, as Member, American Association for Cancer Research, as President from 2016 to 2017, American Society of Clinical Investigation, as Member, European Society for Medical Oncology, as President from 2003 to 2006, Weill Cornell Medical College, as Professor from 2013 to 2018, and Harvard Medical School, as Professor from 2010 to 2012.
Dr. Baselga received his doctorate degree in 1992 from Autonomous University of Barcelona.